Predicting neoadjuvant chemotherapy response in osteosarcoma using T2-based MRI delta-radiomics: a retrospective study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: This study aimed to investigate the application of T2-based MRI delta-radiomics as a novel predictive tool for neoadjuvant chemotherapy (NACT) response in patients with osteosarcoma. MATERIALS AND METHODS: We retrospectively analyzed data from 152 patients with pathologically confirmed osteosarcoma who underwent NACT at our institution. Axial T2-weighted MRI sequences were acquired both at baseline (pre-NACT) and after NACT (post-NACT). After image segmentation and preprocessing, 1158 radiomic features were extracted from the T2-weighted images. We developed and compared four models: the conventional quantitative imaging features-based model (CQIF model), the pre-NACT radiomics model, the post-NACT radiomics model, and the Delta-Radiomics model. Model performance was assessed using the area under the receiver operating characteristic curve (AUC) and accuracy (ACC). RESULTS: Based on histopathological assessment, patients were divided into two groups: good responders (n = 57) and poor responders (n = 95). Significant differences in change rates for tumor diameter and volume were observed between the two groups (P < 0.001). The Delta-Radiomics model demonstrated superior predictive performance compared to other models, achieving an AUC of 0.796, ACC of 0.756, sensitivity of 0.529, specificity of 0.893, PPV of 0.750, and NPV of 0.758 in the test set. However, the Delong test revealed no significant differences among these models, except between the Post-NACT and Delta-Radiomics models (P < 0.05). CONCLUSIONS: T2-based MRI delta-radiomics showed strong predictive value for NACT response in patients with osteosarcoma. This model holds potential for guiding clinical decision-making and improving patient management by identifying responders early in the treatment course.